Related Experiment Video
Updated: Mar 13, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Sharpening the attack on non-small cell lung cancer
Allison Alexander1, Brenda Quincy
1At the time this article was written, Allison Alexander was a student in the PA program at Elon (N.C.) University. She now practices family medicine in Angier, N.C. Brenda Quincy is an associate professor at Butler University in Indianapolis, Ind. The authors have disclosed no potential conflicts of interest, financial or otherwise.
Abstract:
Advanced non-small cell lung cancer (NSCLC) has long been a diagnosis with few treatment options and poor outcomes. However, recent discoveries about the molecular biology of NSCLC are changing the way it is treated. Driver mutations that cause uncontrolled cancer cell proliferation have been discovered in some types of NSCLC. This has led to the discovery of therapies that can target a specific driver mutation in advanced NSCLC and halt cancer progression. This article reviews standard treatment of NSCLC and explores the targetable mutations of NSCLC, available targeted treatments, treatment obstacles, and the future of targeted therapy in NSCLC.
Insights
Targeted therapies are revolutionizing advanced non-small cell lung cancer (NSCLC) treatment by targeting specific driver mutations. This approach offers new hope for improved outcomes in NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Advanced non-small cell lung cancer (NSCLC) historically presents limited therapeutic options and poor prognoses.
- Recent advancements in understanding NSCLC molecular pathology have unveiled critical driver mutations.
- These mutations are key drivers of uncontrolled cancer cell proliferation.
Purpose of the Study:
- To review the current standard treatments for NSCLC.
- To explore targetable mutations within NSCLC.
- To discuss available targeted therapies, challenges, and future directions for NSCLC treatment.
Main Methods:
- Literature review of standard NSCLC treatments.
- Analysis of research on NSCLC molecular drivers.
- Compilation of data on targeted therapies and their efficacy.
- Discussion of treatment obstacles and future prospects.
Main Results:
- Identification of specific driver mutations in NSCLC.
- Development of targeted therapies that inhibit these mutations.
- Demonstration of halted cancer progression in patients receiving targeted treatments.
- Recognition of existing challenges in implementing targeted therapy.
Conclusions:
- Targeted therapies represent a paradigm shift in treating advanced NSCLC.
- Precision medicine approaches hold significant promise for improving patient outcomes.
- Continued research is essential to overcome treatment obstacles and advance NSCLC care.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:46A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer
Published on: August 19, 2025
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers